Track ABSI and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Absci Corp
18105 SE Mill Plain Boulevard, Vancouver, WA, United States, 98683
IPO
2021
Employees
140
Industry
Biotechnology
Sector
Healthcare
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Insider Transactions
Quarterly buy vs. sell activity
Sell (left)Buy (right)
Q1 202610
1
Q3 20250+3
3
2-quarter cumulative
1 sells4 buys
Analyst Ratings
4 analysts covering
Buy100%recommend buy
Buy
4
Hold
0
Sell
0